Informed Consent and Patient Education Informed consent discussions for BPC-157 use should clearly communicate the investigational nature of the peptide, lack of FDA approval, limited human safety and efficacy data, and the reliance on animal studies for much of the supporting evidence
This discrepancy highlights the importance of identifying individuals who are most likely to benefit from NADbased interventions
This information does not claim that BPC-157 or TB-500 treats, cures, or prevents any disease or injury
Primary Handling Editor: Jennifer Sargent, in collaboration with the Nature Medicine team
The Wolverine Blend combines two widely studied peptide fragments, BPC-157 and TB-500, into a single investigational formulation
Causes, Diagnosis, Genetics and Treatment What is a Rare Disease